# LeadArt Biotechnologies

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/leadart-biotechnologies

- Industry: Biotechnology
- Headquarters: Cambridge, US
- Website: www.leadartech.com
- Latest round: Angel (May 1, 2018)
- Investors on record: 2

## About

Based in Massachusetts, US, and founded in 2022, LeadArt Biotechnologies Inc operates as a biotechnology firm that offers a platform that develops pharmaceutical drugs for cancer patients. The company was founded by Feng Ni (CEO), Yufeng Zhao, and JIe Yan (COO). In December 2022, LeadArt Biotechnologies Inc. raised USD 6 million in pre-series A funding led by BlueRun Ventures.

The firm offers a biotechnology platform which is Chemoproteomics and automation dual driver. It offers a target ID platform and a drug screening platform. The LeadArt PAL-AfBPP Process offers probe design, target identification, and binding site identification. The drug screening platform uses LeadArt PAL-AfBPP technology which allows drug screening performed in human live cells.

## Funding rounds

- Angel, May 1, 2018 — Cybernaut Investment Group, KXX Culture Investment

## Investors

- Cybernaut Investment Group (https://capitalatlas.ai/funds/cybernaut-investment-group) — Angel
- KXX Culture Investment (https://capitalatlas.ai/funds/kxx-culture-investment) — Angel